Both strategies can create defined antibody conjugates, but they solve the site-control problem differently. Glycan-directed routes use the conserved Fc carbohydrate as an attachment platform, while engineered cysteine routes create a thiol at a selected amino acid position.
Glycan-directed and engineered cysteine conjugation can both narrow antibody product distributions, but they offer different kinds of control. The glycan route fixes attachment in the Fc carbohydrate region and can begin with an antibody that retains its native amino acid sequence. The cysteine route introduces a chemically addressable thiol at a chosen residue and therefore offers a wider site-selection space.
The appropriate strategy depends on what must remain unchanged, where the payload may be placed, how the antibody is produced, and which analytical evidence is required. Neither route is automatically more homogeneous, efficient, or function-preserving; those outcomes depend on handle preparation, site occupancy, payload behavior, purification, and the stability of the final linkage.
| Decision factor | Glycan-directed route | Engineered cysteine route | Question to resolve |
|---|---|---|---|
| Sequence engineering | Usually not required for Fc-glycan remodeling | Required to install the selected cysteine | Can the antibody be re-expressed and qualified? |
| Site freedom | Centered on the Fc glycan at Asn297 | Broad, subject to folding and function constraints | Is the Fc region an acceptable payload location? |
| Handle preparation | Enzymatic trimming/remodeling and handle installation | Cysteine expression, uncapping or selective reduction | Which intermediate is more controllable? |
| Common coupling | SPAAC or another reaction to the glycan-installed handle | Thiol-selective coupling such as maleimide chemistry | Does the linkage meet stability needs? |
| Primary risks | Glycan heterogeneity, incomplete remodeling, Fc-function effects | Capping, disulfide disturbance, off-target thiols, site-dependent linkage behavior | Which risk is easier to measure and control? |
A native primary sequence can be an important practical constraint when an existing antibody lot must be modified or when creating and requalifying a new sequence variant would delay the program. The central question is whether the selected site and chemistry create the intended molecular product, not merely whether a mass shift can be detected. Mechanistically, glycan-directed methods exploit a conserved post-translational feature rather than adding a new amino acid, whereas cysteine engineering changes the sequence and requires recombinant expression of the variant. The glycan route can reduce protein-engineering work, but the antibody still undergoes enzymatic and chemical processing that must be controlled.
Confirm antibody glycoform distribution, glycan accessibility, sequence ownership, expression availability, and whether a new construct can be produced at the required scale. Treating a native sequence as an unchanged product can be misleading because glycan remodeling intentionally changes Fc carbohydrate composition. State separately whether the project requires a native amino acid sequence, native glycan state, or both. The practical objective is a route that is both chemically interpretable and compatible with the functional assay that will be used to accept the conjugate.
For a controlled study, retain the unmodified parent, the handle-bearing or engineered intermediate, a mock-processed control, and the purified conjugate. Analyze all samples with the same protein quantitation and functional method. Record reagent lot, active concentration, buffer composition, addition sequence, hold time, temperature, and recovered mass. This makes it possible to distinguish a true site effect from batch variation, process exposure, payload behavior, or analytical response bias.
The Fc glycan and a selected cysteine site occupy different structural environments and can affect payload orientation, hydrophobic exposure, Fc interactions, antigen binding, and conjugate stability in different ways. This factor becomes decisive when a project moves from a small model label to the intended payload or from analytical scouting to preparative work. At the molecular level, glycan attachment is constrained to the CH2-domain carbohydrate region, while an engineered cysteine may be placed in Fab or Fc regions after structural screening. A route with greater site freedom is valuable only if the chosen site preserves expression, folding, binding, and the intended antibody functions.
Map the antigen-binding surface, Fc receptor and complement interaction regions, interchain disulfides, known liabilities, and the expected reach of the linker-payload. Selecting a site only because it is solvent exposed can overlook local charge, conformational dynamics, and payload-driven steric effects. Use a small panel of structurally distinct cysteine sites when the optimal region is uncertain, and compare them with the Fc-glycan option under matched conditions. This evidence prevents a high-conversion but poorly defined intermediate from being mistaken for a successful site-specific product.
Set an acceptance rule before the experiment. A useful rule combines intended-site occupancy, off-target burden, monomer recovery, loading distribution, and the assay result most closely connected to the intended use. Also define a redesign trigger, such as a persistent plateau, loss of function in the unconjugated variant, or selective loss of the target-loaded species. Predefined gates keep a chemically impressive but operationally weak result from advancing without sufficient evidence.
A nominally site-specific platform is useful only when the final distribution, attachment location, residual unconjugated antibody, and off-target products can be measured with sufficient sensitivity. A useful evaluation separates the properties of the starting biomolecule from changes introduced by handle installation, coupling, and purification. From a process perspective, both routes create multiple intermediate states: glycan trimming and handle installation for one, and cysteine expression, capping, reduction, and recapping control for the other. Incomplete preparation can produce underloaded or mixed products even when the final coupling reaction is highly selective.
Plan intact and subunit mass analysis, glycan or thiol-state testing, peptide mapping, DAR or degree-of-labeling analysis, SEC, free-payload measurement, and functional assays. An average DAR close to the target does not prove full occupancy at both symmetric sites or exclude a mixture of unconjugated and overmodified species. Define the analytical acceptance criteria before selecting the platform so that route choice includes what can be demonstrated, not only what can be attempted. A decision should therefore combine conversion, recovered monomer, site occupancy, off-target modification, and retained function rather than optimizing any one metric in isolation.
Confirm the conclusion with an independently prepared batch and, where practical, an orthogonal analytical method. Reproducibility should cover starting-material state, handle activity, conversion, purification recovery, and retained function. If the project will change scale, repeat the critical comparison using representative mixing, reagent addition, filtration, and hold times. Site-specific chemistry is transferable only when the molecular exposure history and product distribution remain controlled.
Use glycan-directed conjugation when the conserved Fc glycan is an acceptable location and avoiding sequence engineering has high value. Use engineered cysteine when residue-level site freedom, linker-environment control, or placement outside the glycan region is more important than the added construct and thiol-management burden.
A glycan-directed workflow treats the Fc carbohydrate as a built-in address for handle installation. In a common chemoenzymatic architecture, an endoglycosidase trims the native glycan, a glycosyltransferase or transglycosylation step installs a defined sugar bearing a reactive handle, and a second reaction attaches the payload. The site originates from glycan biology, while the final bond is formed by a compatible chemical ligation.
This route can produce controlled loading because an IgG contains two Fc N-glycans at symmetry-related Asn297 sites. Actual occupancy depends on the starting glycoforms, enzyme accessibility, completeness of trimming and remodeling, handle integrity, and conversion in the final ligation step.
Native antibody glycans are microheterogeneous, so the first process question is whether the chosen enzymes act consistently across the glycoforms present in the starting material. The design should be judged at the product level because the same nominal chemistry can behave differently at another site, on another protein, or with another payload. In an analytical comparison, differences in terminal sugars, fucosylation, galactosylation, sialylation, and glycan accessibility can influence the efficiency of trimming or remodeling steps. Residual glycoforms can become chemically indistinguishable from low-occupancy species unless the analytical method resolves each intermediate.
Characterize the starting glycan profile and monitor each enzymatic step rather than assessing only the final conjugate. Extending reaction time without confirming enzyme compatibility may increase protein exposure while leaving a resistant substrate population unchanged. Establish a stage-specific mass or glycan assay and use it to decide whether enzyme loading, buffer, or starting-material preparation should be adjusted. If the result remains ambiguous, compare a small site or chemistry panel under matched conditions before adding more reagent or extending the reaction time.
Document both successful and missing product populations. Measure the unreacted intended site, relevant alternative sites, free or degraded payload, aggregates, fragments, and material lost during cleanup. A mass balance across these categories is more informative than optimizing a single peak area. When the balance is incomplete, investigate analytical recovery and physical loss before assigning the gap to slow chemistry or inaccessible protein.
Low final loading can arise from incomplete glycan remodeling or from inefficient coupling of a correctly installed handle, and the remedies for those failures are different. The central question is whether the selected site and chemistry create the intended molecular product, not merely whether a mass shift can be detected. Mechanistically, the enzyme step depends on substrate recognition and access, whereas the second ligation depends on handle availability, reagent stability, steric demand, and effective reactant concentration. Optimizing both steps at once can hide the actual bottleneck and consume expensive payload without improving occupancy.
Measure the installed handle before adding the intended payload, preferably with a small diagnostic probe or a direct analytical readout. A small probe can overestimate conversion for a bulky or hydrophobic payload because it experiences less steric and solubility pressure. Use the diagnostic probe to validate handle formation, then confirm the selected conditions with the real payload and report recovery as well as conversion. The practical objective is a route that is both chemically interpretable and compatible with the functional assay that will be used to accept the conjugate.
For a controlled study, retain the unmodified parent, the handle-bearing or engineered intermediate, a mock-processed control, and the purified conjugate. Analyze all samples with the same protein quantitation and functional method. Record reagent lot, active concentration, buffer composition, addition sequence, hold time, temperature, and recovered mass. This makes it possible to distinguish a true site effect from batch variation, process exposure, payload behavior, or analytical response bias.
The Fc glycan contributes to CH2-domain structure and antibody interactions, so glycan remodeling should be treated as a functional design variable rather than a neutral attachment operation. This factor becomes decisive when a project moves from a small model label to the intended payload or from analytical scouting to preparative work. At the molecular level, changing glycan composition and adding a linker-payload can alter local conformation, steric presentation, and interaction surfaces even when antigen binding in the Fab region remains unchanged. A conjugate may preserve target binding yet differ in Fc-dependent behavior or biophysical stability relevant to the intended research use.
Select functional assays that reflect the actual application, including antigen binding, Fc-receptor interaction, complement-related measurements, or cell-based readouts when relevant. Using antigen binding as the only functional test can miss changes caused by modification in the Fc region. Compare the remodeled intermediate, unconjugated antibody, and final conjugate to distinguish glycan-processing effects from payload effects. This evidence prevents a high-conversion but poorly defined intermediate from being mistaken for a successful site-specific product.
Set an acceptance rule before the experiment. A useful rule combines intended-site occupancy, off-target burden, monomer recovery, loading distribution, and the assay result most closely connected to the intended use. Also define a redesign trigger, such as a persistent plateau, loss of function in the unconjugated variant, or selective loss of the target-loaded species. Predefined gates keep a chemically impressive but operationally weak result from advancing without sufficient evidence.
The glycan route is therefore best managed as a sequence of controlled transformations. A clear stage map should identify the starting glycoforms, trimmed intermediate, handle-bearing glycan, clicked conjugate, and any residual low-occupancy species. This approach makes troubleshooting more direct and prevents the final coupling reaction from carrying the analytical burden for every upstream step.
Engineered cysteine conjugation creates a unique or restricted thiol population by substituting a selected antibody residue with cysteine. The design offers broad placement freedom and uses familiar thiol-reactive chemistries, but the engineered thiol is not necessarily conjugation-ready after expression. It may be oxidized, capped with low-molecular-weight thiols, or affected by neighboring residues.
A robust workflow must protect native disulfides while exposing the engineered cysteine, remove reductant or uncapping byproducts, complete coupling before reoxidation or side reactions, and verify that payload attachment occurred at the intended position.
Candidate cysteine sites should support antibody expression, assembly, and storage before they are judged on conjugation conversion. A useful evaluation separates the properties of the starting biomolecule from changes introduced by handle installation, coupling, and purification. From a process perspective, an unpaired thiol can form mixed disulfides, promote aggregation, alter local folding, or become poorly accessible depending on its structural environment. A highly reactive site is not useful if the antibody variant expresses poorly or develops unacceptable monomer loss.
Screen expression yield, intact mass, free-thiol content, aggregation, thermal behavior, binding, and reaction with a small thiol probe across a focused site panel. Relying only on solvent-accessibility calculations can miss dynamic exposure, local electrostatics, and the chemical state produced during secretion. Advance sites that balance conjugation readiness with antibody quality rather than selecting the variant with the fastest initial labeling rate. A decision should therefore combine conversion, recovered monomer, site occupancy, off-target modification, and retained function rather than optimizing any one metric in isolation.
Confirm the conclusion with an independently prepared batch and, where practical, an orthogonal analytical method. Reproducibility should cover starting-material state, handle activity, conversion, purification recovery, and retained function. If the project will change scale, repeat the critical comparison using representative mixing, reagent addition, filtration, and hold times. Site-specific chemistry is transferable only when the molecular exposure history and product distribution remain controlled.
Many engineered cysteines are secreted in capped or oxidized forms, so a controlled pretreatment may be required before coupling. The design should be judged at the product level because the same nominal chemistry can behave differently at another site, on another protein, or with another payload. In an analytical comparison, reductant can remove mixed-disulfide caps but may also reduce native interchain disulfides if exposure is too strong or too long; subsequent reoxidation may not fully restore the original disulfide pattern. The pretreatment can create off-target thiols and broaden the product distribution before the payload is added.
Measure free thiols, interchain disulfide integrity, subunit pattern, and conjugation readiness after each pretreatment step. Proceeding directly from reduction into coupling without removing reductant can consume maleimide or other thiol-reactive payloads and lower effective reagent concentration. Use the mildest selective activation that exposes the engineered site, remove incompatible reagents promptly, and confirm readiness before payload addition. If the result remains ambiguous, compare a small site or chemistry panel under matched conditions before adding more reagent or extending the reaction time.
Document both successful and missing product populations. Measure the unreacted intended site, relevant alternative sites, free or degraded payload, aggregates, fragments, and material lost during cleanup. A mass balance across these categories is more informative than optimizing a single peak area. When the balance is incomplete, investigate analytical recovery and physical loss before assigning the gap to slow chemistry or inaccessible protein.
The same maleimide payload can show different stability when attached at different engineered cysteines. The central question is whether the selected site and chemistry create the intended molecular product, not merely whether a mass shift can be detected. Mechanistically, local solvent exposure, charge, conformational motion, and the tendency of the succinimide ring to hydrolyze influence exchange and deconjugation behavior. Site selection and linker design cannot be optimized independently, particularly when the payload is hydrophobic or the conjugate will encounter competing thiols.
Run matched stress studies across candidate sites and monitor intact conjugate, released payload, transfer products, aggregation, and binding. A stable result in formulation buffer may not predict behavior in a thiol-containing matrix or during prolonged handling. Choose the site-linker combination from matched stability data, not from coupling conversion alone. The practical objective is a route that is both chemically interpretable and compatible with the functional assay that will be used to accept the conjugate.
For a controlled study, retain the unmodified parent, the handle-bearing or engineered intermediate, a mock-processed control, and the purified conjugate. Analyze all samples with the same protein quantitation and functional method. Record reagent lot, active concentration, buffer composition, addition sequence, hold time, temperature, and recovered mass. This makes it possible to distinguish a true site effect from batch variation, process exposure, payload behavior, or analytical response bias.
Engineered cysteine is attractive because its chemistry is direct and its placement can be designed. That apparent simplicity shifts complexity upstream into variant selection and thiol-state control. A reliable process therefore defines the chemical state of the engineered site before coupling, the integrity of native disulfides after activation, and the stability of the final thioether under conditions that challenge the intended use.
Route selection becomes clearer when the decision is framed as a set of constraints rather than a preference for one technology. The starting antibody, payload, target loading, allowable engineering, functional requirements, available analytical methods, and preparation scale all influence which platform is easier to control.
Glycan-directed conjugation is usually favored when a suitable antibody already exists and re-expression of a new sequence variant is not practical. This factor becomes decisive when a project moves from a small model label to the intended payload or from analytical scouting to preparative work. At the molecular level, the route can use the native primary sequence but requires a compatible Fc glycan and enzymatic processing. Engineered cysteine becomes more attractive when the team controls antibody expression and can evaluate several variants before committing to scale.
Document available antibody mass, sequence access, expression platform, glycan profile, timeline, and whether a new construct can be qualified. Choosing a sequence-preserving route without adequate starting-material characterization can transfer glycan variability into the conjugation process. Match platform selection to the degree of control available over both the antibody construct and the incoming lot. This evidence prevents a high-conversion but poorly defined intermediate from being mistaken for a successful site-specific product.
Set an acceptance rule before the experiment. A useful rule combines intended-site occupancy, off-target burden, monomer recovery, loading distribution, and the assay result most closely connected to the intended use. Also define a redesign trigger, such as a persistent plateau, loss of function in the unconjugated variant, or selective loss of the target-loaded species. Predefined gates keep a chemically impressive but operationally weak result from advancing without sufficient evidence.
The payload can change which attachment region is practical even when both handles are chemically accessible. A useful evaluation separates the properties of the starting biomolecule from changes introduced by handle installation, coupling, and purification. From a process perspective, a bulky protein, oligonucleotide, polymer, or hydrophobic drug-linker can experience steric shielding, increase surface hydrophobicity, or alter antibody orientation differently at the Fc glycan and at an engineered amino acid site. The preferred route for a small dye may not remain preferred for the intended payload.
Compare conversion, monomer recovery, hydrophobic-interaction behavior, charge profile, binding, and relevant functional performance using the real payload or a physically representative surrogate. A surrogate chosen only for convenient detection may fail to model payload size, charge, flexibility, or aggregation tendency. Use a surrogate to screen handle chemistry, then confirm site selection with the intended payload before process lock. A decision should therefore combine conversion, recovered monomer, site occupancy, off-target modification, and retained function rather than optimizing any one metric in isolation.
Confirm the conclusion with an independently prepared batch and, where practical, an orthogonal analytical method. Reproducibility should cover starting-material state, handle activity, conversion, purification recovery, and retained function. If the project will change scale, repeat the critical comparison using representative mixing, reagent addition, filtration, and hold times. Site-specific chemistry is transferable only when the molecular exposure history and product distribution remain controlled.
Both routes can target a nominal loading of two groups per IgG, but the same average value can conceal different molecular populations. The design should be judged at the product level because the same nominal chemistry can behave differently at another site, on another protein, or with another payload. In an analytical comparison, partial remodeling may create zero-, one-, and two-handle glycoforms, while incomplete cysteine activation or coupling may create analogous underloaded variants. Average DAR or degree of labeling should be paired with distribution and site-occupancy evidence.
Use intact and subunit mass measurements, chromatographic distribution methods, and site-resolving mapping to determine whether both symmetric sites are occupied. A mean value near two can arise from a mixture that includes unconjugated antibody and higher-loading species. Set acceptance criteria for distribution, not only average loading, and link those criteria to purification capability. If the result remains ambiguous, compare a small site or chemistry panel under matched conditions before adding more reagent or extending the reaction time.
Document both successful and missing product populations. Measure the unreacted intended site, relevant alternative sites, free or degraded payload, aggregates, fragments, and material lost during cleanup. A mass balance across these categories is more informative than optimizing a single peak area. When the balance is incomplete, investigate analytical recovery and physical loss before assigning the gap to slow chemistry or inaccessible protein.
When both routes appear feasible, compare them in a small matched study. Use the same antibody clone, payload batch, target loading, functional assays, and reporting conventions. The study should separate platform-specific intermediate control from final-product performance so that a clean glycan process is not compared unfairly with an incompletely activated cysteine process, or vice versa.
A matched study should answer three questions: which route reaches the target distribution, which route preserves the required antibody functions, and which route produces a stable, recoverable conjugate with an interpretable impurity profile. The design should be small enough to execute consistently but broad enough to expose platform-specific risks.
Confirm identity, glycan profile, free thiols, aggregation, and baseline binding.
Run glycan remodeling and cysteine activation as separate, monitored operations.
Quantify installed handle or free engineered thiol before adding payload.
Use the same payload batch, target loading, and comparable molar excess.
Track monomer recovery, residual free payload, and process losses.
Measure distribution, site occupancy, binding, stability, and application-specific function.
Include controls that distinguish antibody processing effects from conjugation effects. The central question is whether the selected site and chemistry create the intended molecular product, not merely whether a mass shift can be detected. Mechanistically, a remodeled-but-unconjugated antibody tests glycan processing, while an activated-but-unconjugated cysteine variant tests reduction and reoxidation; mock-exposed controls capture buffer, enzyme, and cosolvent stress. Without these controls, a final binding or stability difference cannot be assigned confidently to the attachment site, payload, or preparative workflow.
Compare each intermediate with its own untreated antibody and carry the most informative controls into functional assays. Using only the parent antibody as a control collapses several process variables into one comparison. Predefine which control answers each causal question and avoid adding controls that do not change an interpretation. The practical objective is a route that is both chemically interpretable and compatible with the functional assay that will be used to accept the conjugate.
For a controlled study, retain the unmodified parent, the handle-bearing or engineered intermediate, a mock-processed control, and the purified conjugate. Analyze all samples with the same protein quantitation and functional method. Record reagent lot, active concentration, buffer composition, addition sequence, hold time, temperature, and recovered mass. This makes it possible to distinguish a true site effect from batch variation, process exposure, payload behavior, or analytical response bias.
Preparative success depends on recovered usable conjugate, not only the percentage converted in the reaction mixture. This factor becomes decisive when a project moves from a small model label to the intended payload or from analytical scouting to preparative work. At the molecular level, glycan enzymes, reduction steps, hydrophobic payloads, filters, and chromatography can each reduce mass balance or enrich a subset of species. A route with slightly lower reaction conversion may deliver more purified monomer and a simpler product than a route with high apparent conversion but substantial loss.
Report protein mass before processing, after handle preparation, after coupling, and after purification together with monomer percentage and payload removal. Concentration-normalized analytical traces can hide losses when mass balance is not recorded. Choose the platform from purified product yield and quality rather than reaction conversion alone. This evidence prevents a high-conversion but poorly defined intermediate from being mistaken for a successful site-specific product.
Set an acceptance rule before the experiment. A useful rule combines intended-site occupancy, off-target burden, monomer recovery, loading distribution, and the assay result most closely connected to the intended use. Also define a redesign trigger, such as a persistent plateau, loss of function in the unconjugated variant, or selective loss of the target-loaded species. Predefined gates keep a chemically impressive but operationally weak result from advancing without sufficient evidence.
The comparison should challenge the linkage and antibody under conditions relevant to storage, assay setup, and sample matrices. A useful evaluation separates the properties of the starting biomolecule from changes introduced by handle installation, coupling, and purification. From a process perspective, glycan-installed triazoles and cysteine-derived thioethers have different chemical liabilities, while payload placement also changes local exposure and protein behavior. A short buffer hold can miss exchange, hydrolysis, aggregation, or functional drift that appears later.
Use time-course intact mass, chromatography, free-payload analysis, and binding or functional assays under selected temperature, light, redox, and matrix conditions. Overly harsh stress can rank routes by artificial degradation pathways unrelated to use. Select stresses from the actual workflow and include one accelerated condition only when its interpretation is clear. A decision should therefore combine conversion, recovered monomer, site occupancy, off-target modification, and retained function rather than optimizing any one metric in isolation.
Confirm the conclusion with an independently prepared batch and, where practical, an orthogonal analytical method. Reproducibility should cover starting-material state, handle activity, conversion, purification recovery, and retained function. If the project will change scale, repeat the critical comparison using representative mixing, reagent addition, filtration, and hold times. Site-specific chemistry is transferable only when the molecular exposure history and product distribution remain controlled.
A rational final choice should document why one platform is preferred for this antibody and payload, which tradeoffs remain, and what evidence supports the selected site. That record is more transferable than a general statement that glycan or cysteine chemistry is superior. It also provides a defensible basis for later changes in payload, scale, or analytical requirements.
It can preserve the amino acid sequence, but the Fc glycan is intentionally trimmed or remodeled. Sequence preservation and glycan preservation are different requirements and should be specified separately.
It offers greater freedom to choose a residue, but site specificity still depends on selective thiol activation, native disulfide integrity, reagent selectivity, and analytical confirmation of off-target products.
Yes, both can target two symmetry-related attachments per IgG. Average DAR alone does not prove that every antibody carries two payloads, so distribution and site occupancy should also be measured.
The answer depends on steric access, linker reach, payload charge and hydrophobicity, and the functions that must be retained. Compare the real payload or a representative surrogate at both sites.
Glycan workflows require stage-specific monitoring of trimming and remodeling, while cysteine workflows require thiol-state and disulfide-integrity measurements. Both need final site, loading, purity, aggregation, and function data.
Not automatically. It should be evaluated with assays that measure the specific Fc-related functions needed for the project, because antigen-binding assays alone may not reveal an Fc effect.
The following sources support the scientific framework, terminology, and method comparisons in this resource.
For an Fc-glycan route, evaluate the incoming glycan state, remodeling requirements, handle installation, and the effect of glycan processing on the antibody intermediate.
For an engineered-cysteine route, develop selective thiol activation and coupling while controlling native disulfides, free-thiol state, electrophile exposure, and linkage stability.
Prepare matched antibody conjugates with the intended payload and loading target so glycan-directed and engineered-cysteine architectures can be compared on the same basis.
Compare intact loading distribution, intended-site occupancy, off-target attachment, aggregation, free payload, antigen binding, and stability for both routes.
Share the antibody format, glycan information if available, sequence-engineering options, payload, target loading, functional requirements, and available analytical data. BOC Sciences can design a staged comparison that identifies which route produces the most useful and verifiable research conjugate.